Nosadini R, Brocco E
Internal Medicine Department, Medical School of the University of Padova.
Exp Clin Endocrinol Diabetes. 1997;105 Suppl 2:1-7. doi: 10.1055/s-0029-1211783.
A rate of albumin excretion rate above 20 micrograms/min is a predicting factor of overt nephropathy in Type I diabetes. It has not yet been established whether this is the case also for Type II diabetes, where microalbuminuria is antecedent to general and cardiovascular mortality but not to end-stage renal disease. The reasons accounting for this discrepancy between Type I and Type II diabetes have not been fully elucidated. In principle two different hypotheses can be postulated to explain these findings. Firstly it can be suggested that overt proteinuria is not detected with similar incidence rates in microalbuminuric patients with the two types of diseases because Type II diabetics are older and more prone to develop cardiovascular events. Therefore these patients would die frequently before developing overt proteinuria not because microalbuminuria is not a predicting factor of End-stage Renal Disease, but rather because the follow-up period is not long enough to monitor the patients till the very moment they develop renal complications. Alternatively it is possible that microalbuminuria reflect a systemic, endothelial and vascular disorder rather than glomerular structural abnormalities in these patients. We have recently described a clustering of clinical features encompassing microalbuminuria, hypertension, peripheral extrahepatic insulin resistance, renal and cardiac hypertrophy and altered cation membrane transport systems, not in the overall Type II diabetic population, but only in a cohort of these patients. Evidences in keeping with a strict association between insulin resistance, hypertension and microalbuminuria in a subgroup of Type II diabetic patients have been recently reported by several authors both in cross-sectional and longitudinal studies. However the hypothesis that microalbuminuria reflects a systemic endothelial and vascular disorder in Type II diabetic patients, does not rule out the possibility that these systemic disturbances are also associated with histologic abnormalities of the kidney. With regard to the characteristics of renal histology in Type II diabetic patients with and without microalbuminuria, preliminary data from our laboratory demonstrate that there is no evidence of any renal disorder other than diabetes in microalbuminuric Type II diabetic patients. More particularly in this subset of patients we observed typical features of diabetic nephropathology (glomerular, tubulo-interstitial and arteriolar changes), while a substantial number of patients with increased albumin excretion rate exhibited either marked tubulo-interstitial lesions or arteriolar hyalinosis or both, in absence of significant glomerular changes. These findings suggest that it is not true that Type II diabetic patients with microalbuminuria show quite often normal renal histology, but rather than hyperglycemia may cause different patterns of renal injury as compared to Type I Diabetes. Furthermore always with regard to renal histology, it has been pointed out that in Type I diabetes glomerulopathy (especially mesangial) is the crucial change, whereas recent studies found considerable structural heterogeneity amongst proteinuric Type II diabetic patients with relatively high incidence of renal diseases other than diabetes. However parallel studies in a small group of micromacroalbuminuric Type II diabetic patients reported the typical glomerular changes, usually shown by Type I diabetic patients with similar patterns of renal damage. The issue of the relationships between microalbuminuria, hypertension and the development of overt nephropathy in Type II diabetes has been also examined in Pima Indians. The clinical scenario found in these patients does closely resemble that of Caucasian Type I diabetic patients.
白蛋白排泄率高于20微克/分钟是I型糖尿病显性肾病的一个预测因素。II型糖尿病是否也是如此尚未确定,在II型糖尿病中,微量白蛋白尿先于总体和心血管死亡率出现,但与终末期肾病无关。I型和II型糖尿病之间这种差异的原因尚未完全阐明。原则上,可以提出两种不同的假说来解释这些发现。首先,可以认为在这两种疾病的微量白蛋白尿患者中,显性蛋白尿的检出率不相似,因为II型糖尿病患者年龄较大,更容易发生心血管事件。因此,这些患者在出现显性蛋白尿之前经常死亡,不是因为微量白蛋白尿不是终末期肾病的预测因素,而是因为随访期不够长,无法监测到患者出现肾脏并发症的那一刻。或者,有可能微量白蛋白尿反映了这些患者的一种全身性、内皮和血管紊乱,而不是肾小球结构异常。我们最近描述了一组临床特征的聚集,包括微量白蛋白尿、高血压、外周肝外胰岛素抵抗、肾和心脏肥大以及阳离子膜转运系统改变,这并非在整个II型糖尿病患者群体中出现,而仅在这些患者的一个队列中出现。最近,几位作者在横断面和纵向研究中都报告了II型糖尿病患者亚组中胰岛素抵抗、高血压和微量白蛋白尿之间存在密切关联的证据。然而,微量白蛋白尿反映II型糖尿病患者全身性内皮和血管紊乱的假说,并不排除这些全身性干扰也与肾脏组织学异常相关的可能性。关于有和没有微量白蛋白尿的II型糖尿病患者的肾脏组织学特征,我们实验室的初步数据表明,微量白蛋白尿的II型糖尿病患者除糖尿病外没有任何肾脏疾病的证据。更特别的是,在这一患者亚组中,我们观察到了糖尿病肾病病理学的典型特征(肾小球、肾小管间质和小动脉变化),而大量白蛋白排泄率增加的患者表现出明显的肾小管间质病变或小动脉玻璃样变性,或两者皆有,而没有明显的肾小球变化。这些发现表明,微量白蛋白尿的II型糖尿病患者肾脏组织学通常正常这一说法并不正确,而是与I型糖尿病相比,高血糖可能导致不同模式的肾脏损伤。此外,同样关于肾脏组织学,有人指出在I型糖尿病中,肾小球病变(尤其是系膜病变)是关键变化,而最近的研究发现,蛋白尿性II型糖尿病患者中存在相当大的结构异质性,除糖尿病外的肾脏疾病发生率相对较高。然而,在一小群微量和大量白蛋白尿的II型糖尿病患者中的平行研究报告了典型的肾小球变化,通常与有类似肾脏损伤模式的I型糖尿病患者相同。皮马印第安人也研究了II型糖尿病中微量白蛋白尿、高血压与显性肾病发展之间的关系问题。这些患者的临床情况与白种人I型糖尿病患者非常相似。